VST BIO is developing VB-001, a monoclonal antibody that targets vascular inflammation and edema with potential applications in acute ischemic stroke, sepsis, and cytokine release syndrome. The company is preclinical and plans to advance VB-001 into first-in-human clinical studies in 2026. Its strategic plans include expanding its therapeutic platform and building core development capabilities to support clinical programs. Financially, VST BIO completed a $45 million Series A led by Coefficient Giving; the article states partners have invested a total of $45 million since the company was founded in 2020. Leadership additions tied to the financing include the appointment of William Sessa to the board. The company is headquartered in San Diego and focuses on first-in-class antibody therapies for vascular-related conditions.

Total raised

$45M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2026